Xenetic Biosciences Inc./$XBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Ticker
$XBIO
Sector
Primary listing
Employees
2
Headquarters
Website
XBIO Metrics
BasicAdvanced
$6.3m
-
-$1.18
2.20
-
Price and volume
Market cap
$6.3m
Beta
2.2
52-week high
$13.93
52-week low
$1.90
Average daily volume
17k
Financial strength
Current ratio
7.926
Quick ratio
7.667
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-70.03%
Operating margin (TTM)
-75.05%
Revenue per employee (TTM)
$1,600,000
Management effectiveness
Return on assets (TTM)
-21.85%
Return on equity (TTM)
-37.01%
Valuation
Price to revenue (TTM)
1.64
Price to book
0.91
Price to tangible book (TTM)
0.91
Price to free cash flow (TTM)
-2.873
Free cash flow yield (TTM)
-34.81%
Free cash flow per share (TTM)
-0.964
Growth
Revenue change (TTM)
23.52%
Earnings per share change (TTM)
-50.29%
3-year revenue growth (CAGR)
18.36%
3-year earnings per share growth (CAGR)
-33.22%
10-year earnings per share growth (CAGR)
-43.85%
XBIO News
AllArticlesVideos
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Accesswire·1 month ago
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Accesswire·1 month ago
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs